A PIK3CA-mutant breast cancer metastatic patient-derived organoid approach to evaluate alpelisib treatment for multiple secondary lesions

• Sara Donzelli,
• Mario Cioce,
• Andrea Sacconi,
• Francesca Zanconato,
• Theodora Daralioti,
• Frauke Goeman,
• Giulia Orlandi,
• Simona Di Martino,
• Vito Michele Fazio,
• Gabriele Alessandrini,
• Stefano Telera,
• Mariantonia Carosi,
• Gennaro Ciliberto,
• Claudio Botti,
• Sabrina Strano,
• Stefano Piccolo,
• Giovanni Blandino

Affiliations

Sara Donzelli

Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute

Mario Cioce

Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome

Andrea Sacconi

Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute

Francesca Zanconato

Department of Molecular Medicine, University of Padua

Theodora Daralioti

Department of Pathology, IRCCS Regina Elena National Cancer Institute

Frauke Goeman

SAFU Unit, IRCCS Regina Elena National Cancer Institute

Giulia Orlandi

Scientific Direction, IRCCS San Gallicano Dermatological Institute

Simona Di Martino

Department of Pathology, Biobank, IRCCS Regina Elena National Cancer Institute

Vito Michele Fazio

Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome

Gabriele Alessandrini

Thoracic Surgery, IRCCS Regina Elena National Cancer Institute

Stefano Telera

Neurosurgery Unit, IRCCS Regina Elena National Cancer Institute

Mariantonia Carosi

Department of Pathology, IRCCS Regina Elena National Cancer Institute

Gennaro Ciliberto

Scientific Direction Office, IRCCS Regina Elena National Cancer Institute

Claudio Botti

Breast Surgery Unit, IRCCS Regina Elena National Cancer Institute

Sabrina Strano

SAFU Unit, IRCCS Regina Elena National Cancer Institute

Stefano Piccolo

Department of Molecular Medicine, University of Padua

Giovanni Blandino

Translational Oncology Research Unit, IRCCS Regina Elena National Cancer Institute